Lung Diseases Cies Search Engine [selected websites]

Loading

Blog Archive

Apr 22, 2008

UCB : Phase II results for CDP791 in non-small cell lung cancer support further clinical development

March 31, 2008 - UCB announces first results of its phase II exploratory study of CDP791, a specific VEGFR-2/KDR inhibitor, in combination with carboplatin and paclitaxel chemotherapy in first line non-small cell lung cancer (NSCLC). Positive improvements were observed on several efficacy endpoints including tumour response rate and time to tumour progression. The data support further late stage clinical development of the drug in first line NSCLC. UCB will now work on the consequent clinical development plans and is evaluating partnership options... UCB's Press Release -